S. Oliver

发表

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

H. Tomkinson, J. Kemp, S. Oliver, 2011, BMC clinical pharmacology.

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

M. Dennis, S. Oliver, M. Davies, 2012, Cancer Chemotherapy and Pharmacology.

Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-eroding mucoadhesive polymeric disk

R. Mcquinn, D. Kvam, S. Oliver, 1995 .

The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.

S. Oliver, M. J. Allen, D. Nichols, 2000, British journal of clinical pharmacology.

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Paul D. Martin, E. Lisbon, S. Oliver, 2014, Clinical Pharmacokinetics.

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

H. Kantarjian, G. Garcia-Manero, E. Jabbour, 2013, Clinical lymphoma, myeloma & leukemia.

The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.

N. Wood, S. Oliver, M. Eve, 2003, British journal of clinical pharmacology.

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

T. Clackson, S. Oliver, D. Dalgarno, 2001, Journal of clinical pharmacology.

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

N. Wood, S. Oliver, L. Purkins, 2003, British journal of clinical pharmacology.

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

P. Gibbs, M. Michael, N. Tebbutt, 2009, Investigational New Drugs.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Paul D. Martin, S. Oliver, T. Marbury, 2015, Clinical therapeutics.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.

A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects

R. Elston, J. Ritter, R. Hamatake, 2019, Clinical pharmacology in drug development.

Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects

S. Oliver, M. A. Hayes, R. Teng, 2010, Drug Metabolism and Disposition.

Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)

H. Kantarjian, G. Garcia-Manero, E. Jabbour, 2010 .

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

Paul D. Martin, S. Oliver, J. Read, 2011, Drugs in R&D.

Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.

S. Oliver, M. J. Allen, D. Nichols, 2002, British journal of clinical pharmacology.

Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.

R. Cowan, M. Ranson, J. Logue, 2010, International journal of clinical pharmacology and therapeutics.

Multiple-Dose Pharmacokinetics and Tolerability of Gemifloxacin Administered Orally to Healthy Volunteers

S. Oliver, In-Chull Kim, C. Ward, 2001, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Tolerability of Gemifloxacin (SB-265805) after Administration of Single Oral Doses to Healthy Volunteers

S. Oliver, In-Chull Kim, C. Ward, 2000, Antimicrobial Agents and Chemotherapy.

The long-term safety and tolerability of ispaghula husk

S. Oliver, 2000, The journal of the Royal Society for the Promotion of Health.

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

S. Oliver, H. Swaisland, M. Taboada, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

M. Peeters, S. Oliver, E. Cutsem, 2009, Cancer Chemotherapy and Pharmacology.

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

Paul D. Martin, S. Oliver, C. Brealey, 2016, Drugs in R&D.

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

Paul D. Martin, D. Surry, S. Oliver, 2016, Clinical pharmacology in drug development.

Metabolism and disposition of the antihypertensive agent moxonidine in humans.

L. Shipley, M. Mitchell, S. Oliver, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers

E. Lenz, J. Kemp, S. Oliver, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

1238 An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function

H. Tomkinson, S. Oliver, H. Swaisland, 2009 .

THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BICALUTAMIDE (‘CASODEX’) ENANTIOMERS

S. Oliver, D. C. Jones, I. Cockshott, 1997, Biopharmaceutics & drug disposition.

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Paul D. Martin, S. Oliver, M. Hutchison, 2012, Clinical therapeutics.

718 POSTER The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer

R. Cowan, M. Ranson, J. Logue, 2007 .

724 POSTER Metabolism of [14C]-ZD4054 in healthy volunteers

E. Lenz, J. Kemp, S. Oliver, 2007 .

Frovatriptan: A Review of Drug‐Drug Interactions

S. Oliver, S. Freestone, A. Stewart, 2002 .

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.

H. Tomkinson, J. Kemp, S. Oliver, 2010, Clinical therapeutics.

The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects

P. Ghahramani, S. Oliver, T. Hammett, 2005 .

Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label, multicenter phase I study

P. Gibbs, M. Michael, N. Tebbutt, 2007 .

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.

S. Oliver, V. Hatorp, C. Su, 1998, International journal of clinical pharmacology and therapeutics.

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

Paul D. Martin, D. Surry, S. Oliver, 2016, Drugs in R&D.

An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects

S. Oliver, Anna J. Metcalfe, J. Dietrich, 2000 .

Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.

Paul D. Martin, S. Oliver, C. Brealey, 2015, Clinical therapeutics.

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Paul D. Martin, S. Oliver, M. Hutchison, 2012, Clinical therapeutics.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.